Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Warrant
(NQ:
LEXXW
)
0.2010
UNCHANGED
Streaming Delayed Price
Updated: 3:57 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Warrant
< Previous
1
2
3
4
5
6
7
Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
April 20, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
April 19, 2022
Via
CannabisNewsWire
Exposures
Product Safety
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 19, 2022
- HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 14, 2022
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
April 13, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
April 13, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
April 12, 2022
Via
CannabisNewsWire
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
- Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 11, 2022
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
March 16, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
February 02, 2022
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
CannabisNewsWire
Lexaria Provides Annual Letter From the CEO
January 27, 2022
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 29, 2021
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms...
Via
TheNewswire.com
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
December 14, 2021
Via
CannabisNewsWire
Exposures
Product Safety
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
November 10, 2021
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
November 03, 2021
Via
CannabisNewsWire
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
November 01, 2021
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Via
CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.